These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 20647704)

  • 1. [Economic burden of cancer patients undergoing oral chemotherapy].
    Koinuma N
    Gan To Kagaku Ryoho; 2010 Jul; 37(7):1230-3. PubMed ID: 20647704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [How Long Should We Continue the Chemotherapy?-From the View Point of Health Economics].
    Koinuma N
    Gan To Kagaku Ryoho; 2016 Jul; 43(7):809-18. PubMed ID: 27431625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cytostatic therapy in cancer--a SBU report].
    Glimelius B; Nygren P; Lamnevik G
    Lakartidningen; 2001 Apr; 98(16):1905-10. PubMed ID: 11370407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Out-of-pocket expenditures of outpatients receiving chemotherapy.
    Moore K
    Oncol Nurs Forum; 1998 Oct; 25(9):1615-22. PubMed ID: 9802056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Economic burden for patients with chronic myelogenous leukemia--healthcare economics and medical governance of cancer].
    Kodama Y; Kami M
    Gan To Kagaku Ryoho; 2010 Apr; 37(4):577-81. PubMed ID: 20414010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical oncologists' views on communicating with patients about chemotherapy costs: a pilot survey.
    Schrag D; Hanger M
    J Clin Oncol; 2007 Jan; 25(2):233-7. PubMed ID: 17210946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacoeconomic and clinical outcomes in oncology using oral chemotherapy.
    Navarro RP; Morrow T; Baran R
    Manag Care Interface; 2002 Jul; 15(7):55-62. PubMed ID: 12143298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Usefulness of instruction by pamphlets in cancer chemotherapy].
    Tsurumi R; Takahashi M; Shimoyama K
    Gan To Kagaku Ryoho; 2010 Aug; 37(8):1531-4. PubMed ID: 20716880
    [No Abstract]   [Full Text] [Related]  

  • 10. Why managed care should provide supportive therapies for cancer patients.
    Rubenstein SA
    Manag Care; 1995 Aug; 4(8):37-9. PubMed ID: 10145013
    [No Abstract]   [Full Text] [Related]  

  • 11. Outpatient cancer drug costs: changes, drivers, and the future.
    Halbert RJ; Zaher C; Wade S; Malin J; Lawless GD; Dubois RW
    Cancer; 2002 Feb; 94(4):1142-50. PubMed ID: 11920485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral blood progenitor cell transplantation: economic issues.
    Yee GC
    Pharmacotherapy; 1998; 18(1 Pt 2):9S-16S. PubMed ID: 9473174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The cost of chemotherapy].
    Lévy C; Bonastre J
    Bull Cancer; 2003 Nov; 90(11):976-82. PubMed ID: 14706901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Economic burden of cancer in South Korea for the year 2005].
    Kim J; Hahm MI; Park EC; Park JH; Park JH; Kim SE; Kim SG
    J Prev Med Public Health; 2009 May; 42(3):190-8. PubMed ID: 19491563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An economic model to reduce the cost of chemotherapy for gynecologic cancer.
    Jacobs VR; Thoedtmann J; Brunner B; Kiechle M
    Int J Fertil Womens Med; 2004; 49(6):274-7. PubMed ID: 15751266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer problems lead list for potential medical marijuana research studies.
    Smigel K
    J Natl Cancer Inst; 1997 Sep; 89(17):1255. PubMed ID: 9293912
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost issues in new disease-modifying treatments for advanced cancer: in-depth interviews with physicians.
    de Kort SJ; Kenny N; van Dijk P; Gevers S; Richel DJ; Willems DL
    Eur J Cancer; 2007 Sep; 43(13):1983-9. PubMed ID: 17616456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacoeconomic aspects of oral cytostatic agents].
    Poquet Jornet JE; Carrera-Hueso FJ; Gasent Blesa JM; Peris Godoy M
    Farm Hosp; 2011 May; 35 Suppl 2():25-31. PubMed ID: 22445506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cost-effectiveness analysis of 5-HT3 receptor antagonist drugs in cancer chemotherapy].
    Ishimaru H; Takayama S; Shiokawa M; Inoue T
    Gan To Kagaku Ryoho; 2008 Apr; 35(4):619-23. PubMed ID: 18408430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. European perspective on the costs and cost-effectiveness of cancer therapies.
    Drummond MF; Mason AR
    J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.